Abstract
The objective of the study was to investigate the association between IL-8 and other biomarkers of endothelial dysfunction (MCP-1, V-CAM, I-CAM) and the disease activity scores in a sample of 54 patients with ankylosing spondylitis (AS) without use of biological agents. Fifty-four AS patients without treatment with anti-TNFs agents between 18 and 80 years old, who met modified New York criteria and at the same time the axial ASAS criteria, were evaluated using an epidemiological questionnaire that included among others clinical data, BASDAI, BASFI, ASQoL, ASDAS and plasma levels of CRP, ESR, MCP-1, IL-8, ICAM-1 and VCAM-1. IL-8 varied in proportion to disease activity rates (BASDAI and ASDAS) p < 0.05, being strongly correlated with the disease activity. The levels of adhesion molecules I-CAM and VCAM, as described in other studies, were positively correlated with predisposing factors for cardiovascular disease. IL-8 has shown to be strongly correlated with clinical markers of disease activity and inflammatory activity and may be an additional variable to the overall assessment of the activity of the AS.
Similar content being viewed by others
References
Dougados M (1995) Diagnostic features of ankylosing spondylitis. Br J Rheumatol 34:301–305
Van Der Linden S, Van Der Heijde D (1998) Ankylosing spondylitis: clinical features. Rheum Dis Clin North Am 24(4):663–676
Sampaio-Barros P, Azevedo VF, Bonfiglioli R, Campos WR, Carneiro SCS, Carvalho MAP et al (2007) Consenso brasileiro de espondiloartropatias: espondilite anquilosante e artrite psoriásica diagnóstico e tratamento—primeira revisão. Rev Bras Reumatol 47(4):233–242
Peters MJ, van der Horst-Bruinsma IE et al (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592
Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172
Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD (2010) The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 8(4):437–449
Onat A, Direskeneli H (2012) Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des 18(11):1465–1477
Kang JH, Chen YH, Lin HC (2010) Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 69(6):1165–1168 (Epub 2010 Apr 7)
Joven J, Rubiés-Prat J, Ras MR, de la Figuera M, Lience E, Masdeu S (1984) High density lipoprotein cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 27(10):1199–1200
Azevedo VF, Pecoits-Filho R (2010) Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int 30(11):1411–1416
Wright HL, Moots RJ, Bucknall RC, Edwards SW (2010) Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 49(9):1618–1631 (Epub 2010 Mar 24)
Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD (2011) Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 31(2):153–164
Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH (2004) Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol 16(1):18–24
Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2–3):69–75
Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL, Feuerstein GZ (1994) Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 75(1):1–7
Apostolakis S, Papadakis EG, Krambovitis E, Spandidos DA (2006) Chemokines in vascular pathology. Int J Mol Med 17:691–701
Baggiolini M, Clark-Lewis I (1992) Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 307(1):97–101
Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA et al (1999) MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718–723
Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL et al (1994) Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 75:1–7
O’Hayre M, Salanga CL, Handel TM, Allen SJ (2008) Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 409:635–649
Conti P, DiGioacchino M (2001) MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 22:133–137
van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368
Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J (2009) The development of Assessment of Spondylarthritis international Society classification criteria for axial spondylarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783 (Epub 2009 Mar 17)
Taylor PC, PetersAM Paleolog E, ChapmanPT Elliott MJ, McCloskey R et al (2000) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthrit Rheum 43:38–47
Limón-Camacho L, Vargas-Rojas MI, Vázquez-Mellado J, Casasola-Vargas J, Moctezuma JF, Burgos-Vargas R, Llorente L (2012) In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis. J Rheumatol 39(4):830–835
Azuz-Lieberman N et al (2005) The involvement of NK cells in ankylosing spondylitis. Int Immunol 17(7):837–845
Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study. Circulation 96:4219–4225
Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L et al (2001) Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358:971–976
Haim M, Tanne D, Boyko V, Reshef T, Goldbourt U, Leor J, Mekori YA et al (2002) Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the bezafibrate infarction prevention (BIP) Study. J Am Coll Cardiol 39:1133–1138
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Azevedo, V.F., Faria-Neto, J.R., Stinghen, A. et al. IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents. Rheumatol Int 33, 1779–1783 (2013). https://doi.org/10.1007/s00296-012-2631-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-012-2631-x